{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T23:28:31Z","timestamp":1792625311223,"version":"4.5.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T00:00:00Z","timestamp":1757289600000},"content-version":"vor","delay-in-days":7,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011022","name":"Vertex Pharmaceuticals Incorporated","doi-asserted-by":"publisher","award":["IIS- ISS-2021-109677"],"award-info":[{"award-number":["IIS- ISS-2021-109677"]}],"id":[{"id":"10.13039\/100011022","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.jcf.2025.09.003","type":"journal-article","created":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T14:26:52Z","timestamp":1757773612000},"page":"894-902","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["The novel CFAbd-Score.kid\u24b8 reveals a significant decline of abdominal symptoms in children with Cystic fibrosis aged 6 through 11 years on Elexacaftor\/Tezacaftor\/Ivacaftor \u2013 first results"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3780-7759","authenticated-orcid":false,"given":"Jochen G.","family":"Mainz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"Sadrieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilith","family":"Bechinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franziska","family":"Duckstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anton","family":"Barucha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Polte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7146-6997","authenticated-orcid":false,"given":"Lutz","family":"Naehrlich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2835-9886","authenticated-orcid":false,"given":"Olaf","family":"Eickmeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"van Dullemen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ute","family":"Graepler-Mainka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Zagoya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcf.2025.09.003_bib0001","unstructured":"Agency E.M. Kaftrio [updated 20\/08 2022. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/kaftrio."},{"issue":"1","key":"10.1016\/j.jcf.2025.09.003_bib0002","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S2213-2600(19)30337-6","article-title":"The future of cystic fibrosis care: a global perspective","volume":"8","author":"Bell","year":"2020","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jcf.2025.09.003_bib0003","series-title":"Taschenatlas Pathophysiologie. 6., vollst\u00e4ndig \u00fcberarbeitete Auflage ed","author":"Silbernagl","year":"2019"},{"issue":"4922","key":"10.1016\/j.jcf.2025.09.003_bib0004","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1126\/science.2475911","article-title":"Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA","volume":"245","author":"Riordan","year":"1989","journal-title":"Science"},{"key":"10.1016\/j.jcf.2025.09.003_bib0005","series-title":"A CF-Manual","author":"Ballmann","year":"2022"},{"issue":"10212","key":"10.1016\/j.jcf.2025.09.003_bib0006","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jcf.2025.09.003_bib0007","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1176815","article-title":"Real-life impact of highly effective CFTR modulator therapy in children with cystic fibrosis","volume":"14","author":"Olivier","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jcf.2025.09.003_bib0008","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.877118","article-title":"Elexacaftor-Tezacaftor-Ivacaftor treatment reduces abdominal symptoms in cystic fibrosis-early results obtained with the CF-specific CFAbd-score","volume":"13","author":"Mainz","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jcf.2025.09.003_bib0009","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.3390\/jcm13061650","article-title":"Scoring abdominal symptoms in people with Cystic Fibrosis","volume":"13","author":"Tabori","year":"2024","journal-title":"J Clin Med"},{"key":"10.1016\/j.jcf.2025.09.003_bib0010","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.jcf.2023.10.001","article-title":"Reduction in abdominal symptoms (CFAbd-Score), faecal M2-pyruvate-kinase and Calprotectin over one year of treatment with Elexacaftor-Tezacaftor-Ivacaftor in people with CF aged \u226512 years - the RECOVER study","volume":"2024 May","author":"Mainz","year":"2024","journal-title":"J Cyst Fibros"},{"issue":"25","key":"10.1016\/j.jcf.2025.09.003_bib0011","article-title":"Validation of the CFAbd-Score.Kid\u24b8, a novel gastrointestinal patient reported outcome measure, specific for children with cystic fibrosis","volume":"S1569-1993","author":"Sadrieh","year":"2025","journal-title":"J Cyst Fibros"},{"issue":"4","key":"10.1016\/j.jcf.2025.09.003_bib0012","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s11136-010-9606-8","article-title":"The COSMIN checklist for assessing the methodological quality of studies on measurement properties of health status measurement instruments: an international Delphi study","volume":"19","author":"Mokkink","year":"2010","journal-title":"Qual Life Res"},{"key":"10.1016\/j.jcf.2025.09.003_bib0013","article-title":"Guidance for industry: Patient-Reported Outcome Measures: Use in medical product development to support labeling claims: draft guidance","year":"2006","journal-title":"Health Qual Life Outcomes"},{"issue":"6","key":"10.1016\/j.jcf.2025.09.003_bib0014","doi-asserted-by":"crossref","first-page":"e226","DOI":"10.1016\/S1470-2045(16)30113-9","article-title":"New European guidance on patient-reported outcomes","volume":"17","author":"Venkatesan","year":"2016","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.jcf.2025.09.003_bib0015","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jval.2013.04.004","article-title":"Pediatric patient-reported outcome instruments for research to support medical product labeling: report of the ISPOR PRO good research practices for the assessment of children and adolescents task force","volume":"16","author":"Matza","year":"2013","journal-title":"Value Health"},{"key":"10.1016\/j.jcf.2025.09.003_bib0016","unstructured":"Kitzinger A. Metacom Symbole. 2023. Available from: https:\/\/www.metacom-symbole.de\/."},{"key":"10.1016\/j.jcf.2025.09.003_bib0017","author":"Bechinger"},{"issue":"4","key":"10.1016\/j.jcf.2025.09.003_bib0018","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s40271-019-00361-2","article-title":"Validity and reliability of a novel multimodal questionnaire for the assessment of abdominal symptoms in people with Cystic Fibrosis (CFAbd-Score)","volume":"12","author":"Jaudszus","year":"2019","journal-title":"The Patient - Patient-Centered Outcomes Res"},{"issue":"5","key":"10.1016\/j.jcf.2025.09.003_bib0019","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0174463","article-title":"Abdominal symptoms in cystic fibrosis and their relation to genotype, history, clinical and laboratory findings","volume":"12","author":"Tabori","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.jcf.2025.09.003_bib0020","doi-asserted-by":"crossref","first-page":"1167407","DOI":"10.3389\/fphar.2023.1167407","article-title":"Dynamics of abdominal symptoms during the start of a new therapy with elexacaftor\/tezacaftor\/ivacaftor using the novel CFAbd-day2day questionnaire","volume":"14","author":"Mainz","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jcf.2025.09.003_bib0021","unstructured":"WHO. BMI-for-age (5-19 years) 2023 [Available from: https:\/\/www.who.int\/tools\/growth-reference-data-for-5to19-years\/indicators\/bmi-for-age."},{"issue":"2","key":"10.1016\/j.jcf.2025.09.003_bib0022","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.jcf.2022.10.006","article-title":"Multicenter prospective study showing a high gastrointestinal symptom burden in cystic fibrosis","volume":"22","author":"Moshiree","year":"2023","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2025.09.003_bib0023","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/5128760","article-title":"Imaging the abdominal manifestations of Cystic fibrosis","volume":"2017","author":"Gillespie","year":"2017","journal-title":"Int J Hepatol"},{"issue":"7","key":"10.1016\/j.jcf.2025.09.003_bib0024","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1080\/17476348.2023.2228194","article-title":"Thinking outside the box: a review of gastrointestinal symptoms and complications in cystic fibrosis","volume":"17","author":"Yule","year":"2023","journal-title":"Expert Rev Respir Med"},{"key":"10.1016\/j.jcf.2025.09.003_bib0025","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s40900-019-0159-x","article-title":"Adapting the James Lind Alliance priority setting process to better support patient participation: an example from cystic fibrosis","volume":"5","author":"Rowbotham","year":"2019","journal-title":"Res Involv Engagem"},{"issue":"8","key":"10.1016\/j.jcf.2025.09.003_bib0026","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1136\/thorax-2023-220100","article-title":"A refresh of the top 10 research priorities in cystic fibrosis","volume":"78","author":"Rowbotham","year":"2023","journal-title":"Thorax"},{"issue":"2","key":"10.1016\/j.jcf.2025.09.003_bib0027","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.jcf.2022.10.003","article-title":"Elexacaftor\/tezacaftor\/ivacaftor and gastrointestinal outcomes in cystic fibrosis: report of promise-GI","volume":"22","author":"Schwarzenberg","year":"2023","journal-title":"J Cyst Fibros"},{"issue":"4","key":"10.1016\/j.jcf.2025.09.003_bib0028","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.jcf.2020.12.021","article-title":"Designing the GALAXY study: partnering with the cystic fibrosis community to optimize assessment of gastrointestinal symptoms","volume":"20","author":"Freeman","year":"2021","journal-title":"J Cyst Fibros"},{"issue":"9","key":"10.1016\/j.jcf.2025.09.003_bib0029","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1080\/003655299750025327","article-title":"Psychometric validation of a constipation symptom assessment questionnaire","volume":"34","author":"Frank","year":"1999","journal-title":"Scand J Gastroenterol"},{"issue":"Suppl 4","key":"10.1016\/j.jcf.2025.09.003_bib0030","doi-asserted-by":"crossref","DOI":"10.1136\/gut.2003.034322","article-title":"Patient assessment of treatment satisfaction: methods and practical issues","volume":"53 Suppl 4","author":"Revicki","year":"2004","journal-title":"Gut"},{"issue":"5","key":"10.1016\/j.jcf.2025.09.003_bib0031","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1080\/00365520510012208","article-title":"Development and validation of the Patient Assessment of Constipation Quality of Life questionnaire","volume":"40","author":"Marquis","year":"2005","journal-title":"Scand J Gastroenterol"},{"issue":"11\u201312","key":"10.1016\/j.jcf.2025.09.003_bib0032","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1111\/apt.14349","article-title":"The PAC-SYM questionnaire for chronic constipation: defining the minimal important difference","volume":"46","author":"Yiannakou","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.jcf.2025.09.003_bib0033","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-17302-4","article-title":"Relation of ultrasound findings and abdominal symptoms obtained with the CFAbd-score in cystic fibrosis patients","volume":"7","author":"Tabori","year":"2017","journal-title":"Sci Rep"},{"issue":"7","key":"10.1016\/j.jcf.2025.09.003_bib0034","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1177\/2050640619841545","article-title":"A high prevalence of chronic gastrointestinal symptoms in adults with cystic fibrosis is detected using tools already validated in other GI disorders","volume":"7","author":"Hayee","year":"2019","journal-title":"United European Gastroenterol J"},{"issue":"2","key":"10.1016\/j.jcf.2025.09.003_bib0035","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.jcf.2023.01.010","article-title":"Diabetes is associated with increased burden of gastrointestinal symptoms in adults with cystic fibrosis","volume":"22","author":"Caley","year":"2023","journal-title":"J Cyst Fibros"},{"issue":"6","key":"10.1016\/j.jcf.2025.09.003_bib0036","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02029-2022","article-title":"Long-term safety and efficacy of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis and at least one F508del allele: 144-week interim results from a 192-week open-label extension study","volume":"62","author":"Daines","year":"2023","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.jcf.2025.09.003_bib0037","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1164\/rccm.202301-0021OC","article-title":"Long-term safety and efficacy of Elexacaftor\/Tezacaftor\/Ivacaftor in children aged \u22656 years with cystic fibrosis and at least one F508del Allele: a phase 3, open-label clinical trial","volume":"208","author":"Wainwright","year":"2023","journal-title":"Am J Respir Crit Care Med"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199325015826?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199325015826?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T07:34:52Z","timestamp":1779953692000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199325015826"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":37,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S1569199325015826"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2025.09.003","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The novel CFAbd-Score.kid\u24b8 reveals a significant decline of abdominal symptoms in children with Cystic fibrosis aged 6 through 11 years on Elexacaftor\/Tezacaftor\/Ivacaftor \u2013 first results","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2025.09.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society.","name":"copyright","label":"Copyright"}]}}